Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

83 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Serum CCL7 Is a Novel Prognostic Biomarker of Metastatic Colorectal Cancer.
Chidimatsu H, Tsunedomi R, Nakagami Y, Xu M, Nakajima M, Nakashima-Nakasuga C, Tomochika S, Yoshida S, Suzuki N, Watanabe Y, Matsui H, Shindo Y, Tokumitsu Y, Iida M, Takeda S, Ioka T, Ueno T, Tanabe T, Hoshii Y, Hazama S, Nagano H. Chidimatsu H, et al. Among authors: tsunedomi r. Anticancer Res. 2023 Jan;43(1):105-114. doi: 10.21873/anticanres.16139. Anticancer Res. 2023. PMID: 36585204
Predictive biomarkers for the outcome of vaccination of five therapeutic epitope peptides for colorectal cancer.
Hazama S, Takenouchi H, Tsunedomi R, Iida M, Suzuki N, Iizuka N, Inoue Y, Sakamoto K, Nakao M, Shindo Y, Kanekiyo S, Tokumitsu Y, Yoshimura K, Maeda N, Maeda K, Maeda Y, Matsui H, Yoshino S, Nakamura Y, Fujita Y, Hamamoto Y, Okamoto M, Fujita T, Kawakami Y, Oka M. Hazama S, et al. Among authors: tsunedomi r. Anticancer Res. 2014 Aug;34(8):4201-5. Anticancer Res. 2014. PMID: 25075047
miR-125b-1 and miR-378a are predictive biomarkers for the efficacy of vaccine treatment against colorectal cancer.
Tanaka H, Hazama S, Iida M, Tsunedomi R, Takenouchi H, Nakajima M, Tokumitsu Y, Kanekiyo S, Shindo Y, Tomochika S, Tokuhisa Y, Sakamoto K, Suzuki N, Takeda S, Yamamoto S, Yoshino S, Ueno T, Hamamoto Y, Fujita Y, Tanaka H, Tahara K, Shimizu R, Okuno K, Fujita K, Kuroda M, Nakamura Y, Nagano H. Tanaka H, et al. Among authors: tsunedomi r. Cancer Sci. 2017 Nov;108(11):2229-2238. doi: 10.1111/cas.13390. Epub 2017 Sep 22. Cancer Sci. 2017. PMID: 28859241 Free PMC article. Clinical Trial.
IgG response to MHC class I epitope peptides is a quantitative predictive biomarker in the early course of treatment of colorectal cancer using therapeutic peptides.
Kanekiyo S, Hazama S, Takenouchi H, Nakajima M, Shindo Y, Matsui H, Tokumitsu Y, Tomochika S, Tsunedomi R, Tokuhisa Y, Iida M, Sakamoto K, Suzuki N, Takeda S, Yamamoto S, Yoshino S, Okuno K, Udaka K, Kawakami Y, Matsueda S, Ito K, Nagano H. Kanekiyo S, et al. Among authors: tsunedomi r. Oncol Rep. 2018 May;39(5):2385-2392. doi: 10.3892/or.2018.6288. Epub 2018 Mar 1. Oncol Rep. 2018. PMID: 29498403 Clinical Trial.
Overexpression of miR‑221 and miR‑222 in the cancer stroma is associated with malignant potential in colorectal cancer.
Iida M, Hazama S, Tsunedomi R, Tanaka H, Takenouchi H, Kanekiyo S, Tokumitsu Y, Tomochika S, Tokuhisa Y, Sakamoto K, Suzuki N, Takeda S, Ueno T, Yamamoto S, Yoshino S, Fujita K, Kuroda M, Nagano H. Iida M, et al. Among authors: tsunedomi r. Oncol Rep. 2018 Sep;40(3):1621-1631. doi: 10.3892/or.2018.6575. Epub 2018 Jul 13. Oncol Rep. 2018. PMID: 30015977
Intratumoural-infiltrating CD4 + and FOXP3 + T cells as strong positive predictive markers for the prognosis of resectable colorectal cancer.
Kuwahara T, Hazama S, Suzuki N, Yoshida S, Tomochika S, Nakagami Y, Matsui H, Shindo Y, Kanekiyo S, Tokumitsu Y, Iida M, Tsunedomi R, Takeda S, Yoshino S, Okayama N, Suehiro Y, Yamasaki T, Fujita T, Kawakami Y, Ueno T, Nagano H. Kuwahara T, et al. Among authors: tsunedomi r. Br J Cancer. 2019 Oct;121(8):659-665. doi: 10.1038/s41416-019-0559-6. Epub 2019 Sep 6. Br J Cancer. 2019. PMID: 31488881 Free PMC article.
83 results